215 results about "ALI - Acute lung injury" patented technology

The invention features methods of treating a subject having a lung disorder such as lung inflammation and injury, by administering antithrombin III through pulmonary delivery.

A patient is monitored for a medical condition such as acute lung injury (ALl) by operations including: (i) receiving values of a plurality of physiological parameters for the patient; (ii) computing an ALl indicator value based at least on the received values of the plurality of physiological parameters for the patient; and (iii) displaying a representation of the computed ALl indicator value on a display (14, 22). The computing operation (ii) may employ various inference algorithms trained on a training set comprising reference patients to distinguish between reference patients having ALl and reference patients not having ALl, or may employ an aggregation of two or more such inference algorithms. If patients in an ICU are monitored, the display (22) may simultaneously display a diagrammatic representation of each patient including an identification of the patient and a representation of the ALl indicator value for the patient.

The described invention provides compositions and methods for treating a susceptible subject at risk of pulmonary complications of an acute lung injury caused by a severe infection with a respiratory virus and for restoring lung function to donor lungs. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles (EVs) comprising one or more miRNAs and a pharmaceutically acceptable carrier. The population of EVs can be derived from a patient who has recovered from an infection with the respiratory virus or has been exposed to anti-viral antibodies through treatment, can be derived from MSCs of a normal healthy individual, can be modified by a viral vector, or can be synthetic.

The present invention relates to the use of modified factor VI[ for manufacture of medicaments for treatment of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS) in humans.

The invention relates to preparation and a purification production process of mesenchymal stem cells (MSCs) derived exosomes, and application of the exosomes as a non-cell therapy in the treatment of acute lung injury. The MSCs deriving the exosomes belong to the wall adhesion type of stem cells, and the preparation and purification process have the characteristics that (1) parathyroid hormone is added specially for the preparation of MSCs condition medium, and (2) discontinuous Ficoll density gradient method and immunomagnetic beads separation and purification method are combined for separation and purification so as to obtain the exosomes. Rat acute lung injury (ALI) model experiments confirm that the exosomes can be used for treatment of ALI, so as to lay the foundation for the realization of non-stem cell therapies to substitute stem cells therapies.

The invention provides a medicament for treating infectious diseases, a preparation method and the application thereof. The medicament is prepared from scutellaria baicalensis, jasmine, erigeron breviscapus and cholic acid, and has the following effects: by aiming at the central link--inflammatory reaction of an infectious disease, removing harmful substances such as inflammatory mediators, free radicals and the like, and improving the local microcirculation state, thereby alleviating the pathological damages caused by inflammations; meanwhile, the medicament has the function of regulating the overall internal environment, and can effectively treat lower respiratory tract infection and acute lung injury induced by infection; and the effective substances and functional mechanism of the medicament are relatively clear.

The invention discloses an application of eupatorium sesquiterpene components in preparing a drug for resisting acute lung injury. Eupatorium sesquiterpene components are made into a veterinary drug. A technical solution provided by the invention comprises the steps of making the eupatorium sesquiterpene componentsinto a veterinary drug; inducing acute lung injury in mice by using lipopolysaccharide (LPS) in a manner of in-vivo dosing to the mice; then determining a lung wet/dry ratio of the mice with the acute lung injury, the content of nitric oxide (NO) and protein in a bronchoalveolar lavage fluid (BALF); detecting activities of myeloperoxidase (MPO) and superoxide dismutase (SOD) in lung tissue homogenate, the content of tumor necrosis factor-alpha (TN-alpha), interleukin-6 (IL-6) and interleukin-1[beta] (IL-1[beta]) in the BALF and the content of complement C3 and C3c in blood serum; and observing pathological changes of lung tissues of the mice after H&E staining. Results show that eupatorium sesquiterpene components of eupalinolide F, eupalinolide G, eupalinolide H, eupalinolide I and eupalinolide K have activity for resisting the acute lung injury.

The invention discloses separation and preparation of a euphorbia factor L2 and a novel application of the euphorbia factor L2 to treatment of acute lung injury. The euphorbia factor L2 is a diterpeneester compound extracted and separated from semen euphorbiae lathyridis serving as a traditional Chinese medicinal material and displays good treatment effects on a lipopolysaccharide induced acute lung injury mouse model, and the euphorbia factor L2 has exact functions of resisting inflammatory diseases such as the acute lung injury and can be combined with auxiliary materials to prepare a medicine for resisting the inflammatory diseases such as the acute lung injury of a respiratory system or combined with other medicines for treating the acute lung injury in application.

The invention discloses an application of a chlorogenic acid nano powder inhalation in a medicine for treating acute lung injury. The chlorogenic acid nano powder inhalation is prepared with a chlorogenic acid nano medicine delivery system selected from the dosage forms of lipidosomes, nano-particles, nano-emulsions and micro-emulsions with or without addition of an auxiliary material. The medicine delivery system is dried into solid powder and is then mixed with a carrier to prepare the chlorogenic acid nano powder inhalation. The nano powder inhalation is stable, is easy to enter the deep parts of lung tissue, allows targeted positioning, is convenient to carry and use and has advantages on treatment of the acute lung injury. The chlorogenic acid nano powder inhalation is used for treating acute lung injuries caused by infection, shock, smoking, wound, poisoning, inhalation of simulative gas, irradiation, high-oxygen and low-oxygen atmospheres and the like. The simulative gas herein comprises phosgene, diphosgene, triphosgene, chlorine, nitrogen oxides, formaldehyde, dimethyl sulfate, hydrogen chloride, hydrogen bromide, hydrogen fluoride, ammonia, ozone and sulfur dioxide.

The invention discloses a carbonic oxide inhalator which comprises a control part, a measuring circuit part and a CO-air mixing device. The CO-air mixing device is provided with a CO inlet, an air inlet and a mixed gas outlet. The control part comprises a computer and a displayer. The measuring circuit part comprises a pressure sensor, a current amplifier, a filter and an A/D convertor, wherein the pressure sensor measures the gas pressure of input CO gas, air and mixed gas, current amplification and filtering are conducted on the gas pressure through the current amplifier and the filter respectively, then the gas pressure is converted into a digital signal through the A/D convertor and is input into the computer, and the computer analyzes data of the measuring circuit part and outputs a control command. The carbonic oxide inhalator is used for treating diseases such as pulmonary arterial hypertension, ARDS, respiratory failure caused by acute lung injury, hypoxic ischemic brain damage and shock.

The invention discloses a cefaclor medicinal composition and an acute lung injury protection effect thereof. The cefaclor medicinal composition contains cefaclor and a natural product compound (I) having a novel structure and separated from dry rhizome of Grassleaf Sweelflag Rhizome, and cefaclor and the natural product have lung injury prevention and treatment effects in the individual action process; and cefaclor and the natural product have further improved lung injury prevention and treatment effects when being combined, so cefaclor and the natural product can be used to develop lung injury prevention and treatment medicines. Compared with medicines in the prior art, the medicinal composition has protruding characteristics and substantial progresses.

The invention relates to the technical field of medicine, in particular to an application of a TIPE2 (tumor necrosis factor-alpha induced protein 8 like-2) agonist in immunoregulation drugs for treating endotoxin sepsis complicated with acute lung injury. A model of the endotoxin sepsis complicated with acute lung injury is established, the protection effect testing of the TIPE2 agonist on the sepsis complicated with acute lung injury is performed, and the regulating function of a TIPE2 agonist on the sepsis immune system is achieved, so that the organism damage caused by excessive activation of the immune system can be prevented. According to the invention, exact laboratory data is provided for treatment of sepsis complicated with acute lung injury by the aid of the TIPE2 agonist, and corresponding scientific basis is further provided for an immunomodulatory therapeutic mechanism with the application of the TIPE2 agonist clinically.

The present invention discloses a use of cholesterol-modified HuR interference siRNA in preparation of drugs for treating acute lung injury caused by sepsis. According to the present invention, the related HuR interference siRNA is an artificially-synthesized and cholesterol-modified small nucleic acid drug; with intravenous administration, results show that the HuR siRNA can be richly distributed in lung tissue, enter lung cells, inhibit a plurality of 3'-UTR of mRNA of inflammatory factors having HuR binding sites, and promote TNFalpha RNA degradation so as to inhibit acute lung injury induced by bacterial lipopolysaccharide (LPS), wherein TNFalpha expression can be inhibited; and the small nucleic acid drug provides significant release effects for lung inflammation, is applicable for intravenous administration, inhalation administration or intratracheal administration, and is the small nucleic acid drug having application values and prospects and provided for treating acute lung injury under the premise of lack of effective and related acute lung injury treatment nucleic acid drugs in the prior art.

The invention discloses a method for establishing an acute lung injury animal model, and relates to the technical field of bioengineering. The method for establishing the acute lung injury animal model comprises the following steps: anesthetizing and fixing an experimental animal; inducing acute lung injury of the experimental animal by combining hydrochloric acid with mechanical ventilation; andevaluating the degree of acute lung injury. According to the method, acute pathological injury of the lung of the experimental animal is induced by combining hydrochloric acid with mechanical ventilation, the animal model of acute lung injury can be constructed, and the animal model shows typical characteristics of acute lung injury, such as dyspnea, lung tissue edema and lung tissue fibrosis. Themodel can be used for basic research in the related field of acute lung injury, and lays an experimental animal foundation for exploring the pathogenesis of acute lung injury.

A compound of formula (I) or a salt thereof are provided:

wherein R¹, X and R³ are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

The invention relates to a method for preparing a NO2 adsorption reducing material, which belongs to a method for preparing a gas purifying material and solves the problems of higher micropore proportion, lower mesopore proportion and low NO2 selective adsorption of active carbon prepared by the traditional preparation method. The method sequentially comprises the steps of carbonization, activation and modification processing. The invention can obtain active carbon with high specific surface area, the specific surface areas of a mesopore and a micropore are obviously improved, and the specific surface area of the mesopore is improved to more than 40 percent; and the prepared adsorption reducing material can be used for purifying an inspiratory nitric oxide gas treating relevant diseases, such as acute lung injury and persistent pulmonary hypertension of the new born, high altitude pulmonary edema, lung transplantation reperfusion injury, acute respiratory failure, pulmonary hypertension, and the like, and also be used for separating a NO and NO2 mixed gas to produce a NO gas with high purity.

The invention belongs to the technical field of medicines for preventing and treating acute lung injury, and discloses application of a fritillaria heterosteroid alkaloid monomer, namely application of the fritillaria heterosteroid alkaloid monomer in preparation of medicines for treating, relieving or preventing lung injury. Lung injury is acute lung injury induced by LPS. The lung injury can also be caused by influenza virus infection, bacterial infection and/or fungal infection. The fritillaria heterosteroid alkaloid monomer comprises dehydroobberidine and peimisine. The invention further discloses a preparation method of the fritillaria heterosteroid. According to the invention, corresponding representative compounds, namely dehydroobberidine and peimisine, are selected for an activity experiment for preventing and treating the acute lung injury, and the two natural small-molecule alkaloid monomers, namely dehydroobberidine and peimisine, are determined to have good activity for preventing and treating the acute lung injury, and can obviously relieve lung inflammation and pulmonary edema conditions; the new application disease range of fritillaria plants is widened, and a reliable direction and basis are provided for development of safe and effective new drugs for acute lung injury.